Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan

Daiichi Sankyo Company, Limited and Gustave Roussy announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan, two of Daiichi Sankyo’s lead DXd antibody drug conjugates, in lung and breast cancer.
[Daiichi-Sankyo]
Press Release

Continue reading “Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan”

Bookmark

No account yet? Register

0
Share

Slug and E-Cadherin: Stealth Accomplices?

This perspective article highlights Slug functions in mammary epithelial cells and breast cancer as a “non-epithelial-mesenchymal transition factor” in basal epithelial cells and stem cells with focus reports that demonstrate co-expression of Slug and E-cadherin.
[Frontiers in Molecular Biosciences]
Abstract

Continue reading “Slug and E-Cadherin: Stealth Accomplices?”

Bookmark

No account yet? Register

0
Share

Targeting Disseminated Estrogen-Receptor-Positive Breast Cancer Cells in Bone Marrow

Investigators utilized a 3D co-culture model incorporating estrogen receptor-positive breast cancer cells and bone marrow mesenchymal stem cells to represent disseminated tumors cells in a bone marrow niche.
[Oncogene]
Abstract

Continue reading “Targeting Disseminated Estrogen-Receptor-Positive Breast Cancer Cells in Bone Marrow”

Bookmark

No account yet? Register

0
Share

Development and Implementation of the SUM Breast Cancer Cell Line Functional Genomics Knowledge Base

The SUM Breast Cancer Cell Line Knowledge Base provides information on the derivation of each cell line, provides protocols for the proper maintenance of the cells, and provides a series of data mining tools that allow rapid identification of the oncogene signatures for each line.
[NPJ Breast Cancer]
Full Article

Continue reading “Development and Implementation of the SUM Breast Cancer Cell Line Functional Genomics Knowledge Base”

Bookmark

No account yet? Register

0
Share

Clinical Trials Rebound After COVID-19 Crash, but Can Enrollment Gains Continue?

For the hundreds of thousands of people enrolling in clinical trials every year—and for whom experimental therapies can offer a last hope—a new report provides some welcome news: Enrollment in clinical studies in the United States is on the rebound after disruptions caused by the COVID-19 pandemic.
[ScienceInsider]
Press Release

Continue reading “Clinical Trials Rebound After COVID-19 Crash, but Can Enrollment Gains Continue?”

Bookmark

No account yet? Register

0
Share

Science Money Slashed in EU’s €1.8-Trillion Budget Deal

A historic €1.8-trillion (US$2.1-trillion) budget deal reached by European Union (EU) leaders to fund its next seven years — and its recovery from the coronavirus pandemic — has left scientists and research advocates disappointed.
[Nature News]
Press Release

Continue reading “Science Money Slashed in EU’s €1.8-Trillion Budget Deal”

Bookmark

No account yet? Register

0
Share

The Role of Genetic Polymorphism within PD-L1 Gene in Cancer

The expression of PD-L1 in tumors has been described in many histological types of cancer: melanoma, lung cancer, breast and ovarian, pancreatic and esophagus adenocarcinoma, kidney tumors and bladder cancers as well as in hematopoietic malignancies.
[Experimental and Molecular Pathology]
Kula, A., Dawidowicz, M., Kiczmer, P., Seńkowska, A. P., & Świętochowska, E. (2020). The role of genetic polymorphism within PD-L1 gene in cancer. Review. Experimental and Molecular Pathology, 104494. https://doi.org/10.1016/j.yexmp.2020.104494 Cite
Abstract

Continue reading “The Role of Genetic Polymorphism within PD-L1 Gene in Cancer”

Bookmark

No account yet? Register

0
Share

The Career Cost of COVID-19 to Female Researchers, and How Science Should Respond

Early data on the effects of the coronavirus pandemic on scientific-publishing output suggest that female researchers, particularly those at early-career stages, are the hardest hit. Submissions to preprint servers, such as arXiv, rose more quickly for male authors than for female authors as nations adopted social-isolation measures.
[Nature News]
Press Release

Continue reading “The Career Cost of COVID-19 to Female Researchers, and How Science Should Respond”

Bookmark

No account yet? Register

0
Share

EU Leaders Slash Science Spending in €1.8 Trillion Deal

Following a marathon EU summit in Brussels, national leaders agreed to a €1.8 trillion, seven-year budget and pandemic recovery fund that will spend €81 billion on Horizon Europe, the main EU research program.
[Science Insider]
Press Release

Continue reading “EU Leaders Slash Science Spending in €1.8 Trillion Deal”

Bookmark

No account yet? Register

0
Share

‘Ethically Troubling.’ University Reopening Plans Put Professors, Students on Edge

Come August, hundreds of universities across the United States are poised to reopen their campuses with a mix of online and in-person courses. Only a handful are aiming for an entirely online semester. But as the machinery of higher education cranks back into action, faculty, staff, and students are voicing concerns that, with COVID-19 cases surging in many parts of the country, employees are being forced to put their health—and the health of others—at unnecessary risk.
[ScienceInsider]
Editorial

Continue reading “‘Ethically Troubling.’ University Reopening Plans Put Professors, Students on Edge”

Bookmark

No account yet? Register

0
Share

Pioneering Duplication Detector Trawls Thousands of Coronavirus Preprints

Amid concerns that the torrent of research papers on COVID-19 could be leading to an excess of sloppy work, a computer scientist who develops automated programs to spot duplicate images in research papers is running his software across the world’s coronavirus preprints. So far, his efforts have yielded mixed success and some controversy.
[Nature News]
Press Release

Continue reading “Pioneering Duplication Detector Trawls Thousands of Coronavirus Preprints”

Bookmark

No account yet? Register

0
Share

LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis

Scientists showed that LEFTY1, a secreted inhibitor of NODAL/SMAD2 signaling, was produced by mammary progenitor cells and, concomitantly, suppresses SMAD2 and SMAD5 signaling to promote long-term proliferation of normal and malignant mammary epithelial cells.
[Cell Stem Cell]
AbstractGraphical Abstract

Continue reading “LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis”

Bookmark

No account yet? Register

0
Share
Share